FDA Drops New Cheat Sheets for Generic Drug Makers
Published Date: 5/22/2026
Notice
Summary
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
Analyzed Economic Effects
5 provisions identified: 5 benefits, 0 costs, 0 mixed.
Draft BE Study Design Guidance
The FDA posted new draft product-specific guidances that provide product-specific recommendations on the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). These draft guidances are available on FDA's website and are intended for industry use in planning BE studies.
Specific Drugs Listed For Guidance
FDA published lists of active ingredients for which new draft product-specific guidances (Table 1) and revised draft guidances (Table 2) are available, including drugs such as amlodipine besylate, telmisartan, carboplatin, warfarin sodium, albuterol sulfate, aripiprazole, and many others. Companies developing generic versions of the listed active ingredients can consult the corresponding draft guidances posted on FDA's website.
Public Comment Deadline Set
FDA is accepting electronic or written comments on these draft guidances and must receive comments by July 21, 2026 for consideration before FDA begins work on the final versions. Comments submitted to https://www.regulations.gov will be posted publicly unless submitted as confidential written/paper submissions following FDA instructions.
Final Guidances Reflect FDA Thinking
The notice states that when finalized, these guidances will represent FDA's current thinking on product-specific BE study design to support ANDAs, but they do not establish any rights and are not binding on FDA or the public. The notice also states you may use an alternative approach if it satisfies applicable statutes and regulations.
FDA Will Consider Cost Comments
FDA will consider comments on costs or cost savings that the guidances may generate as it develops the final guidances, noting relevance to Executive Order 14192. Stakeholders may submit cost-related comments for FDA's consideration during finalization.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
Previous / Next Documents
Previous: 2026-10275 — UL LLC: Application for Expansion of Recognition and Proposed Modification to the NRTL Program's List of Appropriate Test Standards
UL LLC wants to expand its role as a trusted safety tester and add a new test standard to the official list. This means more products can get checked faster and safer, helping businesses and workers alike. If you have thoughts, speak up by June 8, 2026—no fees or costs are changing right now!
Next: 2026-10278 — National Vaccine Injury Compensation Program: Revised Amount of the Average Cost of a Health Insurance Policy
The National Vaccine Injury Compensation Program just updated the average monthly cost of a health insurance policy to $742.53. This change affects anyone involved in vaccine injury claims and helps keep compensation fair and up-to-date. The new amount took effect as soon as it was sent to the Court in 2026, reflecting a 5% increase from last year.